Company Overview
About Kenvue
Kenvue Inc. is a Skillman, New Jersey-based consumer health company — publicly traded on the New York Stock Exchange (NYSE: KVUE) as an S&P 500 Consumer Staples component — marketing and selling over-the-counter medicines, skin health and beauty products, and essential health products through iconic consumer brands including Tylenol (pain and fever relief), Band-Aid (wound care), Neutrogena (skin care), Johnson's (baby care), Listerine (oral care), Aveeno (skincare), Motrin/Advil (ibuprofen pain relief), Zyrtec (allergy), Nicorette (smoking cessation), Neosporin (antibiotic ointment), and Benadryl through approximately 22,000 employees in 165 countries. Kenvue was separated from Johnson & Johnson through an IPO in May 2023 (the largest US IPO of 2023) and a tax-free distribution of J&J's remaining 89.6% stake to J&J shareholders in August 2023 — creating the world's largest pure-play consumer health company by market capitalization, with J&J retaining no ownership. In fiscal year 2024, Kenvue reported revenues of approximately $15.5 billion, with organic growth facing headwinds from lower cold/cough/flu season severity (Tylenol, Zyrtec, Benadryl volume sensitive to respiratory illness intensity), competitive pressure in skin health (Neutrogena competing with Korean beauty brands, Cerave, and pharmacy private label), and macroeconomic consumer trading down to lower-price alternatives in some markets. CEO Thibaut Mongon leads Kenvue's strategy of investing in the brand superiority of its household name portfolio while improving operational efficiency in the post-spinoff period (implementing Kenvue's own supply chain infrastructure, IT systems, and organizational structure previously shared with J&J).
Business Model & Competitive Advantage
Kenvue's consumer health brand portfolio model creates competitive advantages through the household name recognition and shelf-space permanence of trusted OTC health brands: Tylenol's #1 position in the US acetaminophen pain relief category (held for decades despite FDA-mandated labeling changes and generic competition) reflects consumer trust in a brand associated with safe, effective fever and pain management for children and adults — with pediatricians recommending Tylenol by brand name to parents, creating a healthcare professional endorsement that private label acetaminophen cannot easily replicate. Band-Aid's adhesive bandage category dominance (Band-Aid accounting for 60%+ of US adhesive bandage sales as a genericized trademark — where "Band-Aid" means "adhesive bandage" in American English — creating the market where being named Band-Aid is itself the competitive advantage) demonstrates how Kenvue's brands have become synonymous with their product categories. Listerine's antiseptic mouthwash positioning (clinical efficacy claims backed by FDA monograph compliance — Listerine is the only mouthwash with FDA-approved oral health claims for gingivitis reduction) sustains premium pricing versus private label mouthwashes in drugstore and grocery OTC aisles.
Competitive Landscape 2025–2026
In 2025, Kenvue competes in over-the-counter consumer health, skin care, and oral care against Haleon (LON: HLN, Advil, Sensodyne, Theraflu, Chapstick — UK consumer health spun off from GSK and Pfizer), Procter & Gamble (NYSE: PG, Crest, Vicks, Metamucil, Pepto-Bismol), and Bayer AG (ETR: BAYN, Claritin, Alka-Seltzer, Aspirin consumer health portfolio) for retail pharmacy shelf space, consumer brand preference in OTC health categories, and digital health commerce channel growth. The talc litigation exposure (Kenvue assumed liability for talc claims related to Johnson's Baby Powder from J&J at the spinoff — ongoing mass litigation alleging talc caused mesothelioma and ovarian cancer) represents the most significant legal risk for Kenvue independent of its operating performance. Neutrogena's competition from affordable Korean beauty (CeraVe, La Roche-Posay, and drugstore skincare brands gaining market share through dermatologist recommendations) challenges Neutrogena's premium dermatologist-recommended skincare positioning. The 2025 strategy focuses on Tylenol and Listerine brand equity reinforcement through digital and TV advertising, Neutrogena skin health positioning differentiation from competitive skincare brands, and talc litigation resolution management.
The Kenvue Story
Founders
Company Timeline
Major milestones in Kenvue's journey
Leadership Team
Meet the leaders behind Kenvue
Kirk Perry
Kirk Perry became CEO of Kenvue on November 2, 2025, after serving as Interim CEO since July 2025. He joined Kenvue's Board in December 2024 and most recently served as President and CEO of Circana. Prior to Circana, Perry was President of Global Client and Agency Solutions at Google and spent 23 years at Procter & Gamble in various leadership roles.
Amit Banati
Amit Banati joined Kenvue as CFO effective May 12, 2025, bringing three decades of finance and operations experience. He previously served as Vice Chairman and CFO of Kellanova (formerly Kellogg Company), where he played a key role in the company's 2023 separation and financial strategy.
Thibaut Mongon
Thibaut Mongon led Kenvue as CEO from its spin-off from Johnson & Johnson in 2023 until July 2025. He previously served as J&J's Executive Vice President and Worldwide Chair of Consumer Health. Mongon guided the company through its IPO and initial year as an independent entity.
Paul Ruh
Paul Ruh served as Kenvue's CFO during the company's separation from Johnson & Johnson and its first year as a public company. He departed in May 2025 as part of the company's strategic review and leadership transition.
Open Positions
Reddit Discussions
Key Differentiators
Market Leader
Kenvue is recognized as a market leader in the Consumer Goods sector, demonstrating strong industry presence and customer trust.
Enterprise Scale
With $15500M in revenue, Kenvue operates at enterprise scale with proven market validation.
Frequently Asked Questions
Not So Random Others
Altria
Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and s
H&M (Hennes & Mauritz)
H&M Hennes & Mauritz is a Swedish multinational fashion retailer founded in 1947, operating brands including H&M, COS, & Other Stories, ARKET, and Weekday. The company runs approximately 4,100 stores
AbbVie
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Sp
Brisk
Brisk is a functional beverage brand offering ready-to-drink iced tea and juice drinks, jointly owned by PepsiCo and Unilever under the Lipton brand partnership. Launched in the 1990s, Brisk positione
Hermes Robotics
Hermes Robotics is an autonomous mobile robot (AMR) and warehouse automation company developing robots and software for logistics and fulfillment operations in warehouses, distribution centers, and ma
Hey Telo
Hey Telo is a Berlin-based AI voice agent company building phone-answering and administrative automation specifically for Germany's 1 million+ independent craftsman businesses (Handwerksbetriebe) — HV
Compare Kenvue with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Kenvue? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Kenvue Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Kenvue vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →